Viridian takes on Horizon
Early data in thyroid eye disease impress, but unanswered questions include the size of the market.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Aldeyra's tears of joy fail to move investors
Aldeyra gets a win in its second pivotal dry eye trial of reproxalap, but only after some serious tinkering.
Significant readouts for small players
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Angiogenesis 2022 – Regeneron and Bayer see positive signs for long-acting Eylea
The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?
